Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to:
- Evaluate the safety and toxicity of tolfenamic acid when used with gemcitabine and
radiation therapy in patients with locally advanced or metastatic pancreatic cancer.
- Determine the maximum-tolerated dose (MTD) of tolfenamic acid when used with gemcitabine
and radiation in pancreatic cancer.
- Characterize the pharmacokinetic profile of tolfenamic acid when used with gemcitabine
and radiation.
- Assess the anti-tumor response to tolfenamic acid when used with gemcitabine and
radiation in patients with advanced pancreatic malignancies.